Insider · CIK 0001588395
Joel David Mayersohn
Files at CTOR (CITIUS ONCOLOGY, INC.). First filing -, latest -.
In brief
Joel David Mayersohn files SEC Form 4 as director at CTOR (CITIUS ONCOLOGY, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Joel David Mayersohn has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Dec 22, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Dec 1, 2025 |
| Sep 19, 2025 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Common Stock | +300,000 | $0.00 | $0 | 321,228 | Sep 23, 2025 |
| Jul 28, 2025 | CTOR CITIUS ONCOLOGY, INC. | JOther Common Stock | +21,228 | $0.00 | $0 | 21,228 | Aug 7, 2025 |
| Dec 12, 2024 | CTOR CITIUS ONCOLOGY, INC. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Dec 16, 2024 |
Questions about Joel David Mayersohn
Answered from the filings on this page, as of the latest one.
Is Joel David Mayersohn buying or selling?
Joel David Mayersohn has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Joel David Mayersohn's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Joel David Mayersohn has 0.
Where does Joel David Mayersohn file Form 4?
Joel David Mayersohn has filed Form 4 at CTOR (CITIUS ONCOLOGY, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.